PRO: Procalcitonin has clinical utility in children with community-acquired pneumonia

Todd A. Florin*, Derek J. Williams

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Procalcitonin (PCT) is a useful, albeit imperfect, diagnostic aid that can help clinicians make more informed decisions around antibiotic use in children with lower respiratory tract infections (LRTI), including communityacquired pneumonia (CAP). Recent data suggest that a very low PCT concentration has a high negative predictive value to identify a population of children at low risk of typical bacterial infections. Although the preponderance of data on the clinical utility of PCT in LRTI come from adult studies, the potential for benefit is likely greatest in paediatric CAP and other LRTIs where viral aetiologies predominate, yet antibiotics are frequently prescribed.

Original languageEnglish (US)
Article numberdlab158
JournalJAC-Antimicrobial Resistance
Issue number4
StatePublished - Dec 1 2021

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Immunology and Allergy
  • Microbiology
  • Immunology


Dive into the research topics of 'PRO: Procalcitonin has clinical utility in children with community-acquired pneumonia'. Together they form a unique fingerprint.

Cite this